<DOC>
	<DOCNO>NCT00550355</DOCNO>
	<brief_summary>This study design evaluate safety tolerability multiple intravenously administer dos PD 0360324 patient rheumatoid arthritis receive methotrexate .</brief_summary>
	<brief_title>Dose-Escalating Multiple Dose Study PD-0360324 Combination With Methotrexate Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis RA least 6 month base upon American College Rheumatology ( ACR ) 1987 Revised Criteria . Must treat methotrexate ( ≥7.5 mg/week ≤25 mg/week ) least 16 week immediately prior enrollment . The dose methotrexate must stable least 6 week prior enrollment . Females childbearing potential require simultaneously use 2 effective contraceptive method , 1 must barrier ( condom , diaphragm cervical cap ) spermicide . Nonvasectomized men must willing abstain sexual intercourse willing use condom addition female partner use another form contraception , woman could become pregnant time first dose study medication completion follow procedure Contact local site inclusion criterion . Diagnosis inflammatory arthritis ( eg , spondyloarthropathies ) ; noninflammatory arthritis musculoskeletal condition ( eg , osteoarthritis , fibromyalgia ) , investigator 's opinion , may interfere clinical assessment . Evidence active latent infection Mycobacterium tuberculosis ( TB ) . Use etanercept , anakinra , oral DMARDs exception methotrexate , within 4 week prior enrollment . Use biological DMARDs within 8 ( adalimumab infliximab ) 12 ( abatacept ) 56 ( rituximab ) week prior enrollment . Use oral corticosteroid , acetaminophen , NSAIDs , opioids permit within dose range define protocol . Contact local site inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>